Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trial

Bruno François, Thorbjørn Grøfte, Vincent Huberlant et al.|The Lancet Respiratory Medicine|2023

Cited by 76